Skip to content

Vera Therapeutics

US · VERA #2739 by market cap Listed 2021
25.45 -1.30 -4.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
  • Total institutional ownership fell 2.7 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
117.14% -2.67pp
Institutions
278 +3
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund57.82%
Hedge Fund34.66%
VC/PE Fund18.53%
Public Company4.73%
Individual/Insider0.88%
Private Company0.87%
Government Pension Fund0.25%
Insurance Company0.20%
Endowment Fund0.14%

Top holders as of 2026-09-30

BlackRock 7.92% · 5.73M sh
Avoro Capital Advisors LLC 7.92% · 5.72M sh
Longitude Capital Management Co., LLC 7.46% · 5.39M sh
T. Rowe Price Group, Inc. 5.55% · 4.01M sh
Deep Track Capital, LP 5.53% · 4.00M sh
Deerfield Management Company, L.P. 5.42% · 3.92M sh
State Street Global Advisors 4.57% · 3.30M sh
Kynam Capital Management, LP 4.00% · 2.89M sh
Vanguard Capital Management, LLC 4.47% · 3.22M sh
Sofinnova Investments, Inc. 3.86% · 2.79M sh
FMR 3.86% · 2.79M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 16 sells

NameRoleStake
Marshall Fordyce Chief Executive Officer 0.40%
Beth Seidenberg Independent Director 0.19%
Sean Grant Chief Financial Officer 0.09%
Joseph Young Senior VP of Finance & Chief Accounting Officer 0.07%
Jason Carter Former Chief Legal Officer 0.07%
Andrew Cheng Independent Director 0.02%
Laurence Skelton -- 0.01%
Robert Brenner Chief Medical Officer 0.01%
David Johnson Chief Opearating Officer 0.01%
Patrick Gerald Enright Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-14 Marshall Fordyce Chief Executive Officer Derivative Exercise and Sale -18,500 $2.90–37.00
2026-09-10 Joseph Young Senior VP of Finance & Chief Accounting Officer Derivative Exercise and Retained +5,000 $3.94
2026-09-01 Marshall Fordyce Chief Executive Officer Derivative Exercise and Sale -18,500 $2.90–35.12
2026-08-02 Nancy Boman -- Other Acquisition +44,987 --
2026-08-02 Nancy Boman -- Other Derivative Acquisition +63,011 $32.23
2026-07-06 Marshall Fordyce Chief Executive Officer Derivative Exercise and Sale -46,250 $2.90–43.59
2026-06-22 Marshall Fordyce Chief Executive Officer Derivative Exercise and Sale -18,500 $2.90–38.43
2026-05-20 Michael Morrissey Independent Chairperson Other Derivative Acquisition +17,084 $34.35
2026-05-20 Patrick Gerald Enright Independent Director Other Derivative Acquisition +17,084 $34.35
2026-05-20 Beth Seidenberg Independent Director Other Derivative Acquisition +17,084 $34.35
2026-05-20 Scott William Morrison Independent Director Other Derivative Acquisition +17,084 $34.35
2026-05-20 James Meyers Independent Director Other Derivative Acquisition +17,084 $34.35
2026-05-20 Andrew Cheng Independent Director Other Derivative Acquisition +17,084 $34.35
2026-05-20 Christy Oliger Independent Director Other Derivative Acquisition +17,084 $34.35
2026-05-20 Kimball Hall -- Other Derivative Acquisition +17,084 $34.35
2026-05-11 Marshall Fordyce Chief Executive Officer Derivative Exercise and Sale -18,500 $2.90–37.09
2026-04-13 Marshall Fordyce Chief Executive Officer Automatic Disposition -22,951 $43.66–45.51
2026-03-22 Jane Wright-Mitchell Chief Legal Officer Other Acquisition +42,403 --
2026-03-22 Jane Wright-Mitchell Chief Legal Officer Other Derivative Acquisition +56,850 $40.73
2026-03-12 Joseph Young Senior VP of Finance & Chief Accounting Officer Derivative Exercise and Retained +10,000 $3.94

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vera Therapeutics discussion 0 comments

Add a comment